Detect early-stage liver cancer with epiLiver, a next-generation liquid biopsy optimized for accuracy and clinically tested for reliability.

This is a liquid biopsy for early detection of liver cancer that detects conversion of patients with chronic hepatitis or healthy controls to early-stage liver cancer HCC. This is a next-generation sequencing assay that is fully optimized and clinically tested. Targets were clinically validated in studies in Yuan Hospital in Beijing and published in Clinical Epigenetics 2018. epiLiver has PCT world patent protection in the U.S., Europe, Canada, Indonesia, India, and Japan. 


There are no reviews yet.

Be the first to review “epiLiver”

Your email address will not be published. Required fields are marked *

Scroll to Top